Skip to main content
. Author manuscript; available in PMC: 2010 Nov 24.
Published in final edited form as: Circulation. 2009 Nov 9;120(21):2077–2087. doi: 10.1161/CIRCULATIONAHA.109.884403

Figure 3. Intramyocardial injection of CPCeP improves cardiac function 12-weeks post infarction.

Figure 3

(A-C) Electrocardiographic assessment of AWD (A), EF (B), and FS (C), in sham (■, orange, n=8), vehicle (●, black, n=9), CPCe (▲, blue, n=8), and CPCeP (◆, green, n=9), 12-weeks post-infarction (mean ± SEM). (D-F) Cardiac function of sham (orange, n=5), vehicle (black, n=5), CPCe (blue, n=5), and CPCeP (green, n=5) were evaluated using in vivo hemodynamic measurements of LVDP (D), LVEDP (E), and dP/dT (F) 12-weeks post-intramyocardial injection (mean ± SEM). φp<.05, φφp<.01, φφφp<.001 compared to sham; #p<.05, ##p<.01, ###p<.001 compared to vehicle, * p<.05, **p<.01, ***p<.001 compared to CPCe. Echocardiography significant (p<.05) by two-way repeated measures ANOVA.